<DOC>
	<DOCNO>NCT02698280</DOCNO>
	<brief_summary>The purpose study determine whether bevacizumab nimustine effective treatment recurrent high grade glioma explore whether subgroup sensitive therapeutic protocol .</brief_summary>
	<brief_title>Bevacizumab Nimustine Patients With Recurrent High Grade Glioma</brief_title>
	<detailed_description>Although anti-angiogenesis therapy glioblastoma ( GBM ) show promise , GBMs often develop resistance treatment within month week salvage therapy . There still effective marker predict response rate bevacizumab . So investigators initiate single-arm Phase II study evaluate efficacy tolerability bevacizumab nimustine regimen explore predictive marker patient recurrent high-grade glioma .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nimustine</mesh_term>
	<criteria>Histological diagnosis primary tumor highgrade glioma ( WHO III IV ) All patient complete radiotherapy chemotherapy primary glioma Enhanced MRI magnetic resonance spectroscopy show unequivocal evidence tumor recurrence progression . Those patient underwent surgical resection tumor recurrence also enrol histological diagnosis GBM available , MRI within 3 day operation need . The patient recurrent gliomas n't undergo bevacizumab therapy enrollment . The time enrol 90 day radiation therapy , 28 day operation recurrent tumor prior chemotherapy . Eastern Cooperative Oncology Group score : 02 Written inform consent Laboratory test : Neutrophil count &gt; 1.5*10^9/L , platelet count &gt; 100*109/L , hemoglobin &gt; 8 g/dL , blood urea nitrogen creatinine &lt; 1.5 upper limit normal ( ULN ) , blood total bilirubin conjugate bilirubin &lt; 1.5 ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 ULN , alkaline phosphatase ( AKP ) &lt; 2 ULN Pregnant lactate woman Allergic administer drug Radiation therapy previous 90 day enrollment The patient recurrent gliomas treat bevacizumab therapy enrollment . Acute infection need antibiotic intravenously Participation clinical trial 90 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Nimustine</keyword>
	<keyword>Pathology , Molecular</keyword>
</DOC>